Kura Oncology to Participate in Two Upcoming Investor Conferences
- A panel discussion entitled “Focusing the Laser on Precision Oncology” at Citi’s 14th Annual
Biotech Conference inBoston at9:30 a.m. ET /6:30 a.m. PT onSeptember 5, 2019 ; and
- An analyst-led discussion at
H.C. Wainwright 21st AnnualGlobal Investment Conference inNew York at12:50 p.m. ET /9:50 a.m. PT onSeptember 10, 2019 .
A live audio webcast of both discussions will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available immediately following the event.
About
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s potential for greater depth and breadth across its pipeline, Kura’s ability to bring new treatments to cancer patients in need, and the progress and expected timing of Kura’s drug development programs and clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the
Contacts
Company:
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com
Media:
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com
Source: Kura Oncology, Inc.